US$ 21.19
fda approval ghk cu drug status adds non-injectable GHK-Cu back to Category 1. FDA Thursday re-added non-injectable GHK-Cu to Category 1 of the 503A bulks process after the nomination was withdrawn from further review. Injectable GHK-Cu remains GHK-Cu FDA Status and Compounding
Description
Suitable for studies involving peptide characterization SKU YPB.241 A single-component research material supplied for controlled research environments

BPC-157's action also includes counteracting portal hypertension and liver-stomach hypertension

GHK-Cu (50mg Vial) Dosage Protocol Copper tripeptide for skin remodeling/repair research/educational dosing reference

Allergic Reactions:Rare, but consult your provider if you have specific allergies to injection components or materials

T.ThorsenS.JensenS
